Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Baskent University |
---|---|
Information provided by: | Baskent University |
ClinicalTrials.gov Identifier: | NCT00519870 |
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise test, and endothelin-1 levels.Losartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT.
Condition | Intervention | Phase |
---|---|---|
Pulmonary Hypertension |
Drug: nifedipine, losartan Drug: losartan Drug: Nifedipine, losartan |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension |
Study Start Date: | January 2005 |
Estimated Study Completion Date: | July 2005 |
Arms | Assigned Interventions |
---|---|
I, II: Active Comparator
I: nifedipine II: losartan
|
Drug: nifedipine, losartan
I: nifedipine 30 mg/d II: losartan 50 mg/d
Drug: losartan
II: losartan
Drug: Nifedipine, losartan
I: nifedipine II: losartan
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Serife Savas Bozbas, MD | Baskent University Faculty of Medicine, Department of Pulmonary Disease |
Study Chair: | Fusun Oner Eyuboglu, MD | Baskent University Faculty of Medicine, Department of Pulmonary Disease |
Study ID Numbers: | KA04/127 |
Study First Received: | August 22, 2007 |
Last Updated: | August 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00519870 |
Health Authority: | Turkey: Ministry of Health |
Pulmonary hypertension Angiotensin receptor blocker Calcium channel blocker |
Calcium, Dietary Losartan Respiratory Tract Diseases Hypertension, Pulmonary Lung Diseases |
Vascular Diseases Angiotensin II Nifedipine Hypertension |
Vasodilator Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Calcium Channel Blockers Cardiovascular Agents Reproductive Control Agents Antihypertensive Agents |
Pharmacologic Actions Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Tocolytic Agents Therapeutic Uses Cardiovascular Diseases Anti-Arrhythmia Agents |